U.S. Food et al., 2007-03-09: FDA's 2006-2007 safety alert for Aranesp, Epogen and Procrit, issued 11/16/2006 and updated 2/16/2007 and 3/09/2007, reporting excess serious adverse events and deaths in four new cancer studies.
new studies in patients with cancer found a higher chance of serious and life-threatening side effects and/or death with the use of ESAs
FDA ALERT header and first paragraph
U.S. Food et al., 2007-03-09: FDA's 2006-2007 safety alert for Aranesp, Epogen and Procrit, issued 11/16/2006 and updated 2/16/2007 and 3/09/2007, reporting excess serious adverse events and deaths in four new cancer studies. Web-only FDA page, no PDF edition, hence empty pdf_url. The live fda.gov URL was retired (returns Page Not Found as of this run); the Internet Archive snapshot of 15 May 2007 was opened and quoted, and is the source_url. Regulatory text: no funder/COI. The alert states the studies tested an unapproved dosing regimen, an unapproved population, or a new ESA, and that FDA 'is re-evaluating how to safely use this product class'. Study type: regulatory record.
